Managing drug resistant tuberculosis

BMJ

Volumn 337, Issue 7669, 2008, Pages 564-569

  Grant, Alison ^a,b   Gothard, Philip ^a   Thwaites, Guy ^a,c  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT;

AGE; CALORIMETRY; DNA SEQUENCE; DRUG SENSITIVITY; GENDER; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MICROARRAY ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; UNITED KINGDOM; ADULT; DISEASE TRANSMISSION; HUMAN; MICROBIOLOGICAL EXAMINATION; PRACTICE GUIDELINE; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 51949091535     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a1110     Document Type: Review

References (27)

1. Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, et al. Increasing antituberculosis drug resistance in the United Kingdom: analysis of national surveillance data. BMJ 2008;336:1231-4.
2. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. 2008. www.who.int/tb/publications/2008/ drs_report4_26feb08.pdf
3. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
4. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948;2:769-82.
5. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-79.
6. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005;171:699-706.
7. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001;5:887-93.
8. World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing. 2008. www.who.int/tb/publications/ global_report/2008/pdf/fullreport.pdf
9. Health Protection Agency. Tuberculosis in the UK: annual report on tuberculosis surveillance and control in the UK 2007. London: Health Protection Agency Centre for Infections, 2007.
10. Maguire H, Dale JW, McHugh TD, Butcher PD, Gillespie SH, Costetsos A, et al. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax 2002;57:617-22.
11. Dale JW, Bothamley GH, Drobniewski F, Gillespie SH, McHugh TD, Pitman R. Origins and properties of Mycobacterium tuberculosis isolates in London. J Med Microbiol 2005;54:575-82.
12. Sam IC, Drobniewski F, More P, Kemp M, Brown T. Mycobacterium tuberculosis and rifampin resistance, United Kingdom. Emerg Infect Dis 2006;12:752-9.
13. Tuberculosis Section, Health Protection Agency Centre for Infections. The UK mycobacterial surveillance network report 1994-2003: 10 years of MycobNet. London: Health Protection Agency, 2005. www.hpa.org.uk/web/ HPAwebFile/HPAweb_C/1194947310544
14. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006;355:1539-50.
15. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis 2007;45:1409-14.
16. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2006. www.nice.org.uk/CG033
17. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
18. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-81.
19. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO, 2006. whqlibdoc.who.int/ publications/2006/9241546956_eng.pdf ril 2008)
20. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-26.
21. Shin SS, Furin JJ, Alcantara F, Bayona J, Sanchez E, Mitnick CD. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis 2006;12:687-8.
22. World Health Organization. The stop TB strategy. Geneva: WHO, 2006. whqlibdoc.who.int/hq/2006/WHO_HTM_STB_2006.368_eng.pdf
23. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007;(3):CD003343.
24. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005;54:1-81.
25. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008;8:359-68.
26. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: WHO, 2004. http://whqlibdoc.who.int/hq/2004/ WHO_HTM_TB_2004.330_eng.pdf
27. Escombe AR, Oeser CC, Gilman RH, Navincopa M, Ticona E, Pan W, et al. Natural ventilation for the prevention of airborne contagion. PLoS Med 2007;4:e68.